Resource library


See all videos


Tumor Assessment Using RECIST 1.1 Criteria and Alternative Criteria for Immuno-oncology Trials

See all brochures

White papers

Understanding Novel Response Patterns of Immunotherapies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

See all white papers

Case studies

FDA Inspection

See all case studies

Scientific publications

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials

Hubert Beaumont [1] , Antoine Iannessi [1, 2], Yi Wang [1], Charles M. Voyton [1], Jennifer Cillario [1], Yan Liu [1] – Affiliations: [1] Median Technologies, 1800 Route des Crêtes, 06560 Valbonne, France. [2] Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06100 Nice, France

The aim of this study was to analyze a pool of lung trials that used RECIST 1.1, document the proportion of reader discrepancies and the reader performance through monitoring procedures, and provide suggestions for the reduction of read inconsistency.

See publication
See all scientific publications